🇺🇸 FDA
Pipeline program

Trastuzumab Deruxtecan

D967SC00001

Phase 3 small_molecule active

Quick answer

Trastuzumab Deruxtecan for Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials